This Article Full Text Full Text (PDF) Other Versions of this Article: AAC.00853-06v1 51/2/566    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Whitcomb, J. M. Articles by Petropoulos, C. J. Search for Related Content PubMed PubMed Citation Articles by Whitcomb, J. M. Articles by Petropoulos, C. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2007, p. 566-575, Vol. 51, No. 2
0066-4804/07/$08.00+0     doi:10.1128/AAC.00853-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Development and Characterization of a Novel Single-Cycle Recombinant-Virus Assay To Determine Human Immunodeficiency Virus Type 1 Coreceptor Tropism

Monogram Biosciences, Incorporated, South San Francisco, California 94080

Received 12 July 2006/ Returned for modification 14 August 2006/ Accepted 13 November 2006

Most human immunodeficiency virus type 1 (HIV-1) strains require either the CXCR4 or CCR5 chemokine receptor to efficiently enter cells. Blocking viral binding to these coreceptors is an attractive therapeutic target. Currently, several coreceptor antagonists are being evaluated in clinical trials that require characterization of coreceptor tropism for enrollment. In this report, we describe the development of an automated and accurate procedure for determining HIV-1 coreceptor tropism (Trofile) and its validation for routine laboratory testing. HIV-1 pseudoviruses are generated using full-length env genes derived from patient virus populations. Coreceptor tropism is determined by measuring the abilities of these pseudovirus populations to efficiently infect CD4⁺/U87 cells expressing either the CXCR4 or CCR5 coreceptor. Viruses exclusively and efficiently infecting CXCR4⁺/CD4⁺/U87 cells are designated X4-tropic. Conversely, viruses exclusively and efficiently infecting CCR5⁺/CD4⁺/U87 cells are designated R5-tropic. Viruses capable of infecting both CXCR4⁺/CD4⁺/U87 and CCR5⁺/CD4⁺/U87 cells are designated dual/mixed-tropic. Assay accuracy and reproducibility were established by evaluating the tropisms of well-characterized viruses and the variability among replicate results from samples tested repeatedly. The viral subtype, hepatitis B virus or hepatitis C virus coinfection, and the plasma viral load did not affect assay performance. Minority subpopulations with alternate tropisms were reliably detected when present at 5 to 10%. The plasma viral load above which samples can be amplified efficiently in the Trofile assay is 1,000 copies per ml of plasma. Trofile has been automated for high-throughput use; it can be used to identify patients most likely to benefit from treatment regimens that include a coreceptor inhibitor and to monitor patients on treatment for the emergence of resistant virus populations that switch coreceptor tropism.

Published ahead of print on 20 November 2006.

This article has been cited by other articles:

• Gulick, R. M., Lalezari, J., Goodrich, J., Clumeck, N., DeJesus, E., Horban, A., Nadler, J., Clotet, B., Karlsson, A., Wohlfeiler, M., Montana, J. B., McHale, M., Sullivan, J., Ridgway, C., Felstead, S., Dunne, M. W., van der Ryst, E., Mayer, H., the MOTIVATE Study Teams, (2008). Maraviroc for Previously Treated Patients with R5 HIV-1 Infection. NEJM 359: 1429-1441 [Abstract] [Full Text]  
• Fatkenheuer, G., Nelson, M., Lazzarin, A., Konourina, I., Hoepelman, A. I.M., Lampiris, H., Hirschel, B., Tebas, P., Raffi, F., Trottier, B., Bellos, N., Saag, M., Cooper, D. A., Westby, M., Tawadrous, M., Sullivan, J. F., Ridgway, C., Dunne, M. W., Felstead, S., Mayer, H., van der Ryst, E., the MOTIVATE 1 and MOTIVATE 2 Study Teams, (2008). Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection. NEJM 359: 1442-1455 [Abstract] [Full Text]  
• Tsibris, A. M. N., Sagar, M., Gulick, R. M., Su, Z., Hughes, M., Greaves, W., Subramanian, M., Flexner, C., Giguel, F., Leopold, K. E., Coakley, E., Kuritzkes, D. R. (2008). In Vivo Emergence of Vicriviroc Resistance in a Human Immunodeficiency Virus Type 1 Subtype C-Infected Subject. J. Virol. 82: 8210-8214 [Abstract] [Full Text]  
• Fransen, S., Bridger, G., Whitcomb, J. M., Toma, J., Stawiski, E., Parkin, N., Petropoulos, C. J., Huang, W. (2008). Suppression of Dualtropic Human Immunodeficiency Virus Type 1 by the CXCR4 Antagonist AMD3100 Is Associated with Efficiency of CXCR4 Use and Baseline Virus Composition. Antimicrob. Agents Chemother. 52: 2608-2615 [Abstract] [Full Text]  
• Vandekerckhove, L., Verhofstede, C., Vogelaers, D. (2008). Maraviroc: integration of a new antiretroviral drug class into clinical practice. J Antimicrob Chemother 61: 1187-1190 [Abstract] [Full Text]  
• Huang, W., Toma, J., Fransen, S., Stawiski, E., Reeves, J. D., Whitcomb, J. M., Parkin, N., Petropoulos, C. J. (2008). Coreceptor Tropism Can Be Influenced by Amino Acid Substitutions in the gp41 Transmembrane Subunit of Human Immunodeficiency Virus Type 1 Envelope Protein. J. Virol. 82: 5584-5593 [Abstract] [Full Text]  
• Huang, W., Eshleman, S. H., Toma, J., Fransen, S., Stawiski, E., Paxinos, E. E., Whitcomb, J. M., Young, A. M., Donnell, D., Mmiro, F., Musoke, P., Guay, L. A., Jackson, J. B., Parkin, N. T., Petropoulos, C. J. (2007). Coreceptor Tropism in Human Immunodeficiency Virus Type 1 Subtype D: High Prevalence of CXCR4 Tropism and Heterogeneous Composition of Viral Populations. J. Virol. 81: 7885-7893 [Abstract] [Full Text]